News

Renal Cancer Pipeline Outlook Report 2025: Key 75+ Companies And Breakthrough Therapies Shaping The Future Landscape
In July 2025, Bristol-Myers Squibb announced a study is to assess the safety and efficacy of nivolumab combined with ...
Canadian Medical Association Journal7d
Levothyroxine treatment for subclinical hypothyroidism and risk of adverse renal outcomes: a population-based cohort study
Background: Subclinical hypothyroidism has been linked to adverse renal outcomes, but it is unknown whether treatment of subclinical hypothyroidism reduces the risk of these adverse outcomes. We ...